Amgen's lung cancer drug tarlatamab wins China approval
Published on April 10, 2026.
Amgen's lung cancer drug, tarlatamab, has been approved in China. The drug is used as a targeted immunotherapy for adults with advanced stage of the disease that has worsened despite chemotherapy. It is part of Amgen's pipeline of antibodies that connect a cancer cell and an immune cell. The company did not comment on the launch date or price.
Related Articles
Suffolk Police Searching For Missing East Patchogue Man With Alzheimer's
Suffolk Police are searching for 89-year-old Warren Gerard, missing from East Patchogue, in a 2002 Nissan Frontier, with potential for murder.
Common Vitamin May Reduce Buildup of Alzheimer's Proteins, Study Finds
A study suggests higher vitamin D levels in midlife may reduce tau protein tangles in Alzheimer's disease, though further research is needed to determine its cause and potential treatment.
Park Ridge Farmers Market given OK to offer alcoholic drinks
The Park Ridge Farmers Market will now offer alcohol for a limited time, but only within the area of Cumberland Park, amid local and regional concerns.